Cambrex and AstraZeneca team members at ribbon cutting ceremony to mark long-term supply agreement at Sweden facility.
Cambrex held an opening ceremony with AstraZeneca at its Karlskoga, Sweden site to mark the commencement of a long-term manufacturing agreement between the two companies for a key intermediate.
The announcement follows the completion, in 2017, of both a large-scale, multi-purpose capacity expansion which also includes hydrogenation capabilities and a dedicated continuous flow production unit capable of producing multiple metric tons of high purity advanced intermediates per annum at the Karlskoga facility.
“Cambrex was selected as our manufacturing partner on this long-term intermediate supply agreement as they clearly demonstrated a robust technically and commercially attractive solution, as well as having a good track record in terms of performance and delivery,” Speaking at the ceremony, Juliette White, VP Global External Sourcing, AstraZeneca, said. “We look forward to a successful collaboration with Cambrex.”